Loading clinical trials...
Loading clinical trials...
Open-label, Phase 2 Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia
Conditions
Interventions
AzaCITIDine Oral Tablet
Xospata
Locations
20
France
Amiens CHU
Amiens, France
Angers CHU
Angers, France
Hôpital d'Instruction des Armées PERCY
Clamart, France
CHU Estaing
Clermont-Ferrand, France
Créteil CHU HENRI MONDOR
Créteil, France
Grenoble CHU
Grenoble, France
Start Date
January 13, 2024
Primary Completion Date
October 1, 2026
Completion Date
October 1, 2027
Last Updated
March 24, 2025
NCT06307054
NCT06704152
NCT05237258
NCT06613217
NCT06420063
NCT06486350
Lead Sponsor
French Innovative Leukemia Organisation
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions